Yan Xia

Structure biology by training, now a drug hunter armed with knowledge from most microscopic detail of physical chemical biology to macroscopic pharmacology and toxicology. Founded ADC research center in HDM. Consolidating Huadong ADC Ecosystem to create innovative ADC mordalities. Projects includes ADCs and Abs from early research to development. Specialized in combining novel biology and linker payload for differentiated ADC designs. Past projects include mono-specific ADCs, bi-specific ADCs, novel payload ADCs, dual-payload ADCs cross oncology, metabolic disease and autoimmune disease. Managing ADC Research Center daily operation. Leads Huadong’s R&D strategy in conjugated drug discovery. Discovery to Clinic trackers: HDM2005,2020,2012,2017,2024 NMPA&FDA FIH IND. Clinic trackers: HDM2005 PhII, 2017 PhII

Managing a team of biologists and medicinal chemists in a collaboration project with Exscientia on AI drug discovery for innovative cancer therapeutics. Managing one pre-clinical co-discovery & development project. Led a small group of biochemist, computational structural biologist & biologist to support research in kinase inhibitor discovery, GPCR agonists, PROTAC in diverse therapeutics areas. Side projects include DD in liscence-in or strategic acquisition, R&D strategy, pipeline strategy.